IRIS-A: Phase II Trial in Stage IA HER2-Positive Breast Cancer At ASCO 2026, Ruoxi Wang, MD, PhD, of Fudan University Shanghai Cancer Center, presented IRIS-A findings on adjuvant capecitabine plus trastuzumab in stage IA HER2-positive breast cancer. Five-Year Outcomes with Capecitabine and Trastuzumab: Adjuvant treatment for small, node-negative H
31 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Pancytopenia, a rare presentation of hyperthyroidism
832 Reached2 Comments
Female with History of Amenorrhoea
3103 Reached10 Comments11 Likes
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes